Investors & Media

Multiple opportunities for immuno-oncology

Investors Home

Ziopharm Oncology is focused on advancing the next generation of immunotherapies to weaponize the existing immune system with Controlled IL-12 or introduce new immune system elements with Sleeping Beauty-modified T cells to this fight against cancer. In addition to developing the next generation of immuno-oncology medicines that target multiple types of cancers, we also are targeting the cost and complexity of delivering gene and cell therapies.

Corporate Contacts:

David Connolly, Vice President,
Corp. Comms / IR
(617) 502-1881
dconnolly@ziopharm.com

Mike Moyer
Vice President, Portfolio Strategy
(617) 765-3770
mmoyer@ziopharm.com